Home / Industry / News / USFDA observations in 2022 focus on ancillary infra, written procedures

USFDA observations in 2022 focus on ancillary infra, written procedures

45% observations in 2022 around unavailability of written procedures and facility maintenance, ancillary infrastructure

Premium

4 min read Last Updated : Jun 29 2023 | 11:25 PM IST

Listen to This Article

Around 45 per cent of observations issued by the US drug regulator in 2022 were around unavailability of written procedures, facility maintenance and ancillary infrastructure, shows an analysis of Form 483s issued by the US Food and Drug Administration (USFDA), according to McKinsey.

The analysis shows that the nature of observations made in a Form 483 has been changing over the years. And, observations on issues such as laboratory control and core manufacturing processes have been on the decline.

This implies that core manufacturing processes at Indian sites are more or less stable and under control. And now, the regulatory focus is

Topics : USFDA

What you get on BS Premium?

Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
Pick your 5 favourite companies, get a daily email with all news updates on them.
Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
Preferential invites to Business Standard events.
Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.

VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in